Mackenzie Financial’s GenMark Diagnostics, Inc GNMK Stock Holding History

Mackenzie Financial’s Portfolio GNMK Stock Details GNMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,300	Closed	-$150K	–	1227
2020 Q4	$150K	Buy	+10,300	New	+$137K	﹤0.01%	1004
2016 Q3	–	Sell	-74,800	Closed	-$651K	–	885
2016 Q2	$651K	Hold	74,800	–	–	﹤0.01%	715
2016 Q1	$394K	Hold	74,800	–	–	﹤0.01%	697
2015 Q4	$580K	Buy	74,800 +7,200	+11%	+$55.3K	﹤0.01%	639
2015 Q3	$532K	Buy	67,600 +10,300	+18%	+$95.3K	﹤0.01%	656
2015 Q2	$519K	Hold	57,300	–	–	﹤0.01%	675
2015 Q1	$744K	Buy	57,300 +7,500	+15%	+$98.1K	﹤0.01%	596
2014 Q4	$678K	Buy	49,800 +1,400	+3%	+$15.7K	﹤0.01%	597
2014 Q3	$434K	Buy	+48,400	New	+$521K	﹤0.01%	637

Other funds holding GNMK

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mackenzie Financial's GNMK Position: Q1 2021 in Review

Mackenzie Financial sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 10,300 shares — an estimated $150K sold.

Mackenzie Financial first reported a position in GNMK in Q3 2014 and held it in 9 quarters. The position peaked at $744K in Q1 2015. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

Mackenzie Financial reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
Mackenzie Financial sold 10,300 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $150K.
Mackenzie Financial first reported a position in GenMark Diagnostics, Inc in Q3 2014 and held it in 9 quarters.
Mackenzie Financial's GenMark Diagnostics, Inc position peaked at $744K in Q1 2015.
164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Mackenzie Financial's 13F filing for Q1 2021, filed 14 May 2021.